Orthocell Ltd Market Cap ($109.42 Million)
Market Cap & Net Worth: Orthocell Ltd (OCC)
Orthocell Ltd market cap. Orthocell Ltd (AU:OCC) has a market capitalization of $109.42 Million (AU$154.65 Million) as of November 4, 2026. Listed on the AU stock exchange, this Australia-based company holds position #18643 globally and #577 in its home market, demonstrating a 15.15% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Orthocell Ltd's stock price AU$0.57 by its total outstanding shares 271307941 (271.31 Million). Also see OCC cash flow metrics for how efficiently the company converts equity into cash flow.
Orthocell Ltd Market Cap History (2015–2026)
Orthocell Ltd market cap history from 2015 to 2026. Data shows change from $73.91 Million to $109.42 Million (-0.90% CAGR). Check today's stock price for Orthocell Ltd for real-time trading data and today's change.
Orthocell Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Orthocell Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore OCC year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
27.58x
Orthocell Ltd's market cap is 27.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $72.95 Million | $666.50K | -$3.78 Million | 109.45x | N/A |
| 2017 | $65.27 Million | $529.82K | -$4.18 Million | 123.19x | N/A |
| 2018 | $27.84 Million | $619.18K | -$5.76 Million | 44.96x | N/A |
| 2019 | $94.06 Million | $945.66K | -$5.85 Million | 99.47x | N/A |
| 2020 | $86.39 Million | $719.52K | -$6.15 Million | 120.06x | N/A |
| 2021 | $97.90 Million | $1.02 Million | -$9.04 Million | 96.18x | N/A |
| 2022 | $78.71 Million | $1.53 Million | -$9.11 Million | 51.38x | N/A |
| 2023 | $78.71 Million | $4.24 Million | -$6.25 Million | 18.55x | N/A |
| 2024 | $260.12 Million | $5.32 Million | -$7.18 Million | 48.94x | N/A |
| 2025 | $208.28 Million | $7.55 Million | -$8.57 Million | 27.58x | N/A |
Competitor Companies of OCC by Market Capitalization
Companies near Orthocell Ltd in the global market cap rankings as of November 4, 2026. Also see total assets of Orthocell Ltd for a full breakdown of the balance sheet.
Key companies related to Orthocell Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Orthocell Ltd (2015–2026)
Market capitalization of Orthocell Ltd from 2015 to today. Between 2015 and today, Orthocell Ltd's market cap moved from $73.91 Million to $ 109.42 Million, with a yearly change of -0.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$109.42 Million | -47.47% |
| 2025 | AU$208.28 Million | -19.93% |
| 2024 | AU$260.12 Million | +230.49% |
| 2023 | AU$78.71 Million | 0.00% |
| 2022 | AU$78.71 Million | -19.61% |
| 2021 | AU$97.90 Million | +13.33% |
| 2020 | AU$86.39 Million | -8.16% |
| 2019 | AU$94.06 Million | +237.93% |
| 2018 | AU$27.84 Million | -57.35% |
| 2017 | AU$65.27 Million | -10.53% |
| 2016 | AU$72.95 Million | -1.30% |
| 2015 | AU$73.91 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Orthocell Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $109.42 Million USD |
| MoneyControl | $109.42 Million USD |
| MarketWatch | $109.42 Million USD |
| marketcap.company | $109.42 Million USD |
| Reuters | $109.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Orthocell Ltd
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membr… Read more